Stockscreener 앱 받기
12.22
0.25%
0.075
시간 외 거래:
11.83
-0.395
-3.23%
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Balance Sheet Insights: Day One Biopharmaceuticals Inc (DAWN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Financial Metrics Unveiled: Ginkgo Bioworks Holdings Inc (DNA)’s Key Ratios in the Spotlight - The Dwinnex
How To Trade (DAWN) - Stock Traders Daily
You might want to take a look at Day One Biopharmaceuticals Inc (DAWN) now - SETE News
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer - Seeking Alpha
SG Americas Securities LLC Buys Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of Directors - Yahoo Finance
SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Reviewing Day One Biopharmaceuticals (NASDAQ:DAWN) and Nature’s Sunshine Products (NASDAQ:NATR) - Defense World
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
(DAWN) Trading Report - Stock Traders Daily
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? - Yahoo Finance
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5) - Seeking Alpha
Where are the Opportunities in (DAWN) - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha
(DAWN) On The My Stocks Page - Stock Traders Daily
High Growth Tech Stocks to Watch in December 2024 - Simply Wall St
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat
5 Companies That Celebrated First Approvals in 2024 - BioSpace
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
State Street Corp Sells 3,003 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan
Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Children's Brain Tumor Network Partners with Day One Biopharmaceuticals to Drive New Therapies for Pediatric Brain Tumors - Marketscreener.com
Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com
Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
689,655 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Has $30.31 Million Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Samsara BioCapital LLC Has $2.05 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Fmr LLC Boosts Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
1.54%
자본화:
|
볼륨(24시간):